Humanigen Inc (fka HGENQ)

[cowtown jay]

I was beginning to worry about you, Yooo. It's been 3 weeks since you posted. So, good to know you haven't forgotten about us.

As far as the post you replied to, I was only wondering aloud if lenz may be the common denominator in the success of both trials. Obviously, it was the drug being studied in the PREACH-M trial. But as I said before, I wonder if Kevin resigned from Humanigen's Board, to dedicate his full attention to the IIT of their CAR-T, using lenz as intended by one of our patents, such as this one?

"Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
Patent number: 11673962
Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
Type: Grant
Filed: October 2, 2018
Date of Patent: June 13, 2023
Assignee: HUMANIGEN, INC.
Inventors: Cameron Durrant, Dale Chappell"

https://patents.justia.com/assignee/humanigen-inc